Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

1.

What is the optimal antithrombotic strategy in primary percutaneous coronary intervention?

Sergie Z, Mehran R, Stone GW.

Curr Opin Cardiol. 2012 Jul;27(4):361-7. doi: 10.1097/HCO.0b013e3283540828.

PMID:
22565142
[PubMed - indexed for MEDLINE]
2.

Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.

Hibbert B, MacDougall A, Labinaz M, O'Brien ER, So DY, Dick A, Glover C, Froeschl M, Marquis JF, Wells GA, Blondeau M, Le May MR.

Circ Cardiovasc Interv. 2012 Dec;5(6):805-12. doi: 10.1161/CIRCINTERVENTIONS.112.968966. Epub 2012 Nov 13.

PMID:
23149331
[PubMed - indexed for MEDLINE]
Free Article
3.

Bivalirudin during primary PCI in acute myocardial infarction.

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators.

N Engl J Med. 2008 May 22;358(21):2218-30. doi: 10.1056/NEJMoa0708191.

PMID:
18499566
[PubMed - indexed for MEDLINE]
Free Article
4.

Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.

Olchanski N, Slawsky KA, Plent S, Kado C, Cyr PL.

Hosp Pract (1995). 2010 Nov;38(4):138-46. doi: 10.3810/hp.2010.11.351.

PMID:
21068538
[PubMed - indexed for MEDLINE]
5.

Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial.

Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW.

Circulation. 2010 Jan 5;121(1):43-51. doi: 10.1161/CIRCULATIONAHA.109.878017. Epub 2009 Dec 21.

PMID:
20026777
[PubMed - indexed for MEDLINE]
Free Article
6.

Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.

Bangalore S, Cohen DJ, Kleiman NS, Regev-Beinart T, Rao SV, Pencina MJ, Mauri L; EVENT Registry Investigators, Boston, MA.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):463-73. doi: 10.1161/CIRCINTERVENTIONS.111.961912. Epub 2011 Oct 4.

PMID:
21972401
[PubMed - indexed for MEDLINE]
Free Article
7.

Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty.

Bonello L, de Labriolle A, Roy P, Steinberg DH, Pinto Slottow TL, Xue Z, Kaneshige K, Torguson R, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R.

Cardiovasc Revasc Med. 2009 Jul-Sep;10(3):156-61. doi: 10.1016/j.carrev.2008.12.005.

PMID:
19595396
[PubMed - indexed for MEDLINE]
8.

Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW.

J Am Coll Cardiol. 2008 Sep 2;52(10):807-14. doi: 10.1016/j.jacc.2008.05.036.

PMID:
18755342
[PubMed - indexed for MEDLINE]
Free Article
9.

Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.

Saw J, Lincoff AM, DeSmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ; REPLACE-2 Investigators.

J Am Coll Cardiol. 2004 Sep 15;44(6):1194-9.

PMID:
15364319
[PubMed - indexed for MEDLINE]
Free Article
10.

Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.

Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW.

JACC Cardiovasc Interv. 2011 Feb;4(2):191-7. doi: 10.1016/j.jcin.2010.10.011.

PMID:
21349458
[PubMed - indexed for MEDLINE]
Free Article
11.

Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial).

Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW.

Am J Cardiol. 2009 May 1;103(9):1196-203. doi: 10.1016/j.amjcard.2009.01.030.

PMID:
19406258
[PubMed - indexed for MEDLINE]
12.

The bivalirudin paradox: high evidence, low use.

De Servi S, Mariani G, Mariani M, D'Urbano M.

J Cardiovasc Med (Hagerstown). 2013 May;14(5):334-41. doi: 10.2459/JCM.0b013e32835f1915. Review.

PMID:
23442811
[PubMed - indexed for MEDLINE]
13.

Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial.

Capranzano P, Dangas G.

Expert Rev Cardiovasc Ther. 2012 Apr;10(4):411-22. doi: 10.1586/erc.12.24. Review.

PMID:
22458574
[PubMed - indexed for MEDLINE]
14.

Bivalirudin: a pharmacoeconomic profile of its use in patients with acute coronary syndromes.

Lyseng-Williamson KA.

Pharmacoeconomics. 2011 Apr;29(4):343-59. doi: 10.2165/11206360-000000000-00000. Review.

PMID:
21395353
[PubMed - indexed for MEDLINE]
15.

Bleeding outcomes after routine transradial primary angioplasty for acute myocardial infarction using eptifibatide and unfractionated heparin: a single-center experience following the HORIZONS-AMI trial.

Moody WE, Chue CD, Ludman PF, Chan YK, Narayan G, Millington JM, Townend JN, Doshi SN.

Catheter Cardiovasc Interv. 2013 Sep 1;82(3):E138-47. doi: 10.1002/ccd.24703. Epub 2013 Apr 8.

PMID:
23074143
[PubMed - indexed for MEDLINE]
16.

Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

Lopes RD, Alexander KP, Manoukian SV, Bertrand ME, Feit F, White HD, Pollack CV Jr, Hoekstra J, Gersh BJ, Stone GW, Ohman EM.

J Am Coll Cardiol. 2009 Mar 24;53(12):1021-30. doi: 10.1016/j.jacc.2008.12.021. Erratum in: J Am Coll Cardiol. 2009 Apr 21;53(16):1473.

PMID:
19298914
[PubMed - indexed for MEDLINE]
Free Article
17.

Bivalirudin for patients with acute coronary syndromes.

Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM; ACUITY Investigators.

N Engl J Med. 2006 Nov 23;355(21):2203-16.

PMID:
17124018
[PubMed - indexed for MEDLINE]
Free Article
18.

Safety and efficacy of indigenously developed and manufactured bivalirudin in moderate/high-risk Indian patients undergoing percutaneous coronary intervention: the Bivaflo Registry.

Seth A, Sinha N, Parikh K, Patel T, Hiremath MS, Mehta AB, Chandra P, Pinto B, Sethi KK, Sengottuvelu S.

Indian Heart J. 2008 Jul-Aug;60(4):333-41.

PMID:
19242012
[PubMed - indexed for MEDLINE]
19.

Safety of bivalirudin in patients with coronary artery disease.

Abdel-Wahab M, Richardt G.

Expert Opin Drug Saf. 2012 Jan;11(1):141-50. doi: 10.1517/14740338.2012.628312. Epub 2011 Oct 17. Review.

PMID:
21999110
[PubMed - indexed for MEDLINE]
20.

Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction.

Dauerman HL, Frederick PD, Miller D, French WJ; National Registry of Myocardial Infarction-5 Investigators.

Coron Artery Dis. 2007 Mar;18(2):141-8.

PMID:
17301606
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk